Clinical Trial: An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07665437) titled 'An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS' on June 18.

Brief Summary: The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Study Start Date: July 09

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa

Intervention: DRUG: Remibrutinib

Remibrutinib Dose A and B (oral)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis P...